Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
MOMA Therapeutics has launched with $86 million in series A financing, led by Third Rock Ventures, to develop small-molecule drugs against a family of more than 400 proteins—MOMA calls them molecular machines—that use ATP hydrolysis to “generate force and motion.” Examples include DNA helicases and chromatin remodeling proteins, which regulate gene expression. The company has recruited experts in protein biophysics and cryogenic electron microscopy to target molecular machines implicated in cancer and rare diseases.
This article has been sent to the following recipient: